# Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI

> **NCT03733535** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Dr. Grace Parraga** · enrollment: 29 (actual)

## Conditions studied

- Asthma; Eosinophilic

## Interventions

- **DRUG:** Benralizumab
- **DRUG:** 129 Xenon

## Key facts

- **NCT ID:** NCT03733535
- **Lead sponsor:** Dr. Grace Parraga
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-01
- **Primary completion:** 2022-03-20
- **Final completion:** 2026-12
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2025-08-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03733535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03733535, "Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT03733535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*